Company: ATMCW
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001641172-25-004801
Chunk: 476

Company: ALPHATIME ACQUISITION CORP
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 476
---
 generate any operating revenues until the completion of its initial Business Combination,
at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO.
The Company has selected December 31 as its fiscal year end.

The
Company’s sponsor is Alphamade Holding LP, a Delaware limited partnership (the “Sponsor”). The registration statement
for the Company’s IPO was declared effective on December 30, 2022 (the “Effective Date”). On January 4, 2023, the Company
consummated the IPO of 6,000,000 units (the “Units”). Each Unit consists of one ordinary share of the Company, par value
$0.0001 per share (the “Ordinary Shares”), one redeemable warrant (the “Warrants”) and one right (the “Rights”),
with each Right entitling the holder thereof to receive one-tenth of one Ordinary Share upon the completion of an initial Business Combination,
subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $60,000,000. On
January 6, 2023, Chardan Capital Markets, LLC exercised its over-allotment option (the “Overallotment”), which subsequently
closed on January 9, 2023, to purchase an additional 900,000 Units at a public offering price of $10.00 per Unit, generating additional
gross proceeds to the Company of $9,000,000.

Simultaneously
with the closing of the IPO, the Company completed the sale of 370,500 private units to the Sponsor (the “Private Units”)
at a purchase price of $10.00 per Private Unit, generating gross proceeds to the Company of $3,705,000. Simultaneously with the closing
of the Overallotment, the Company completed the private sale of an additional 38,700 Private Units, at a purchase price of $10.00 per
Private Unit, generating additional gross proceeds to the Company of $387,000. Transaction costs amounted to $4,892,699 consisting of
$1,612,500 of underwriting discount, $2,415,000 of deferred underwriting commission and $865,199 of other offering costs.

Following
the closing of the IPO and the sale of over-allotment units, an aggregate of $70,242,000 of the proceeds from the